Smith & Nephew shares surge on activist Cevian building stake
Activist investor Cevian Capital increased its position in Smith & Nephew to a 5% stake in the British medical equipment maker, making it Smith & Nephew’s second largest shareholder according to reports by Reuters. According to LSEG data, Cervian is known for taking stakes in companies and calling for change.
In recent years, Smith & Nephew has lost significant stock value following an all-time high in early 2020, prior to pandemic restrictions and subsequent world economic events that have impacted the company’s operating margins, according to the Reuter’s report.
Friederike Helfer, a partner at Cevian Capital, told Reuters, “Smith & Nephew owns fundamentally attractive businesses in structurally growing markets, but the company has not generated shareholder value for many years. [We] see the potential to create significant long-term value by improving the operating performance of the company’s businesses. We have high expectations for the board and management to realize this potential,” he added.
According to reports, Smith & Nephew said it would continue to engage with Cevian “as we do with all of our shareholders.”
Smith & Nephew shares were up 7% as a result of the Cervian filing.
Related Articles
-
Payers demand robust evidence that molecular diagnostics and AI/ML technologies demonstrate clear ability to improve overall patient health or healthcare economics even if the technologies themselves don’t directly deliver the final outcome. This disconnect between a technology's function and the…
-
With more than 50 years in the medical device space, SERF SAS is recognized for its innovations in hip implants, including the invention of the original Dual Mobility Cup.
-
Digital vehicle reimbursement solutions not only ensure fair compensation for employees, but also aid companies in managing costs.
-
Nearly 2/3 of device makers say their regulatory intelligence may be insufficient and they lack the resources to complete all product compliance needs this year. See the executive summary of this MedTech Intelligence audience research.
